FDA Provides Development Pathway for Novel Women's Testosterone Therapy with Reduced Breast Cancer Risk
核心洞察
Aviva Bio (搜索) received FDA guidance for developing AVA-291 (搜索) (d3-T), a next-generation testosterone therapy specifically designed for women that resists aromatization to address breast cancer (搜索) safety concerns.
New data to be presented at AACR 2026 shows AVA-291 (搜索) has approximately 1,000-fold lower potential to stimulate breast cancer (搜索) cell proliferation compared to ordinary testosterone.
The company plans to initiate a Phase 1 trial of AVA-291 (搜索) in early 2026, marking a significant milestone for women's hormone therapy development.
Aviva Bio (搜索) has received formal FDA guidance for developing AVA-291 (搜索) (d3-T), a novel testosterone formulation specifically designed for women that addresses longstanding safety concerns around breast cancer (搜索) risk. The biotechnology company announced that the FDA provided development pathway requirements during a Type B meeting, marking a significant milestone for advancing testosterone therapy in a patient population with substantial unmet medical needs.
Novel Molecular Design Addresses Safety Concerns
AVA-291 (搜索) represents a next-generation testosterone designed to retain the hormone's androgen activity while resisting aromatization. This molecular modification is particularly significant given that aromatization of testosterone locally in breast tissue has been linked to increased breast cancer (搜索) risk, a safety concern that has historically limited testosterone therapy development for women.
"For decades, testosterone therapy for women has depended on repurposed male formulations, rather than drugs designed with women's biology and safety considerations in mind," explained Judith A. Boice, PhD, CEO of Aviva Bio (搜索). "Our FDA feedback reinforces the need for a new standard—one anchored in safety, enabled by molecular precision, and developed with regulatory clarity from the start."
The drug utilizes deuterium substitution technology, where select hydrogen molecules in testosterone are replaced with deuterium. According to Boice, "d3-T is a novel, structurally identical form of testosterone where select hydrogen molecules have been substituted with deuterium. This small change creates a significant breakthrough."
Promising Preclinical Safety Data
Supporting AVA-291 (搜索)'s differentiated safety profile, new data accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting in April 2026 demonstrate that the compound has approximately 1,000-fold lower potential to stimulate breast cancer (搜索) cell proliferation compared to ordinary testosterone.
"The data we are presenting at AACR provides mechanistic evidence that AVA-291 (搜索) (d3-T) has a reduced risk of exacerbating breast cancer (搜索) compared with ordinary testosterone," said Bradford C. Sippy, CTO of Aviva Bio (搜索). "This builds on our prior work showing that AVA-291 is resistant to aromatization and highlights the potential clinically differentiated profile."
Broad Development Program Planned
Aviva Bio (搜索) is advancing AVA-291 (搜索) across multiple indications in both women's and men's health where androgen signaling plays a clinically meaningful role but aromatization limits testosterone's therapeutic potential. Potential applications include hormone replacement therapy in menopausal women, treatment for men on testosterone therapy who develop gynecomastia (搜索), addressing muscle loss and low libido in patients on GLP-1 therapy, and treatment of ER-positive breast cancer (搜索).
The company notes that AVA-291 (搜索) shares similar physical properties to testosterone and can be substituted in any current testosterone formulation, potentially facilitating clinical development and eventual commercialization.
Clinical Development Timeline
Aviva Bio (搜索) plans to initiate a Phase 1 trial of AVA-291 (搜索) in early 2026, representing the first step toward bringing a female-specific testosterone therapy to market. The FDA's acknowledgment of the potential breast cancer (搜索) risk associated with testosterone use in women and the agency's guidance on development requirements reflects a shared commitment to addressing this risk through evidence-based development strategies.
The development program represents a potential paradigm shift for women's hormone therapy, moving away from repurposed male formulations toward treatments specifically designed with women's biology and safety considerations in mind.